{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:25:03Z","timestamp":1778462703270,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Following infection with <jats:italic>Mycobacterium tuberculosis<\/jats:italic>, young children are at high risk of developing severe forms of tuberculosis (TB) disease, including TB meningitis (TBM), which is associated with significant morbidity and mortality. In 2022, the World Health Organization (WHO) conditionally recommended that a 6-month treatment regimen composed of higher doses of isoniazid (H) and rifampicin (R), with pyrazinamide (Z) and ethionamide (Eto) (6HRZEto), be used as an alternative to the standard 12-month regimen (2HRZ-Ethambutol\/10HR) in children and adolescents with bacteriologically confirmed or clinically diagnosed TBM. This regimen has been used in South Africa since 1985, in a complex dosing scheme across weight bands using fixed-dose combinations (FDC) available locally at the time. This paper describes the methodology used to develop a new dosing strategy to facilitate implementation of the short TBM regimen based on newer globally available drug formulations. Several dosing options were simulated in a virtual representative population of children using population PK modelling. The exposure target was in line with the TBM regimen implemented in South Africa. The results were presented to a WHO convened expert meeting. Given the difficulty to achieve simple dosing using the globally available RH 75\/50\u00a0mg FDC, the panel expressed the preference to target a slightly higher rifampicin exposure while keeping isoniazid exposures in line with those used in South Africa. This work informed the WHO operational handbook on the management of TB in children and adolescents, in which dosing strategies for children with TBM using the short TBM treatment regimen are provided.<\/jats:p>","DOI":"10.3389\/fphar.2023.1055329","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T09:52:18Z","timestamp":1682416338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis"],"prefix":"10.3389","volume":"14","author":[{"given":"Roeland E.","family":"Wasmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Masini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri","family":"Viney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Verkuijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Brands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: A multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/cid\/ciab725","article-title":"Pharmacokinetics of first-line drugs in children with tuberculosis, using World health organization-recommended weight band doses and formulations","volume":"22","author":"Chabala","year":"2021","journal-title":"Clin. Infect. Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: A systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B5","first-page":"704","article-title":"Intensive short course chemotherapy in the management of tuberculous meningitis","volume":"2","author":"Donald","year":"1998","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S2352-4642(21)00302-3","article-title":"One dose does not fit all: Revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation","volume":"6","author":"Denti","year":"2022","journal-title":"Lancet Child. Adolesc. Heal"},{"key":"B7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/cid\/ciab908","article-title":"Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: A prospective population pharmacokinetic study","volume":"75","author":"Denti","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B8","volume-title":"Circular: Paediatric TB FDC weight-band dosing Tables_24June2021","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tube.2010.07.003","article-title":"The chemotherapy of tuberculous meningitis in children and adults","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: The opti-rif trial","volume":"16","author":"Garcia-Prats","year":"2021","journal-title":"J. Antimicrob. Chemother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/cpt.2044","article-title":"Pharmacokinetics and drug\u2010drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: Importance of genotyping","volume":"109","author":"Gausi","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"019844-19","DOI":"10.1128\/AAC.01984-19","article-title":"Population pharmacokinetics and dosing of ethionamide in children with tuberculosis","volume":"64","author":"Nyberg","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/cid\/ciac208","article-title":"Randomized clinical trial of high dose rifampicin with or without levofloxacin versus standard of care for paediatric tuberculous meningitis: The TBM-KIDS trial","volume":"15","author":"Paradkar","year":"2022","journal-title":"Clin. Infect. Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2334-7-140","article-title":"Culture-confirmed childhood tuberculosis in Cape Town, South Africa: A review of 596 cases","volume":"7","author":"Schaaf","year":"2007","journal-title":"BMC Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0213718","DOI":"10.1371\/journal.pone.0213718","article-title":"High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre","volume":"14","author":"Seijger","year":"2019","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ofac108","DOI":"10.1093\/ofid\/ofac108","article-title":"Comparative effectiveness of regimens for drug-susceptible tuberculous meningitis in children and adolescents: A systematic review and aggregate-level data meta-analysis","volume":"9","author":"Sulis","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials","volume":"71","author":"Svensson","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40262-017-0577-6","article-title":"Evidence-based design of fixed-dose combinations: Principles and application to pediatric anti-tuberculosis therapy","volume":"57","author":"Svensson","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/INF.0000000000000065","article-title":"Short intensified treatment in children with drug-susceptible tuberculous meningitis","volume":"33","author":"van Toorn","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/bcp.14694","article-title":"Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children","volume":"87","author":"Wasmann","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B27","unstructured":"Global tuberculosis report2021"},{"key":"B28","volume-title":"Rapid advice: Treatment of tuberculosis in children","year":"2010"},{"key":"B29","unstructured":"Report of a WHO expert consultation on dosing to enable implementation of treatment recommendations in the WHO consolidated guidelines on the management of TB in children and adolescents2022"},{"key":"B30","volume-title":"Treatment of tuberculosis guidelines","year":"2010"},{"key":"B31","unstructured":"WHO consolidated guidelines on tuberculosis - module 5: Management of tuberculosis in children and adolescents2022"},{"key":"B32","unstructured":"WHO consolidated guidelines on tuberculosis, module 4: Treatment - drug-susceptible tuberculosis treatment2022"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1055329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T09:52:27Z","timestamp":1682416347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1055329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":32,"alternative-id":["10.3389\/fphar.2023.1055329"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1055329","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"1055329"}}